GALT today
$3.29-$0.09 (-2.66%)close Nov 11, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourExpanding
15 minBearish
5 minStrong Bearish
Daily trend turns up above $4.72
Key levels
Resistance$4.00
Resistance$3.52
Support$2.90
Support$2.50
Latest news & SEC filings
NewsGalectin Therapeutics Shares Data at AASLD Liver Meeting 2026
ProductGalectin Therapeutics reports belapectin benefit in NAVIGATE trial analysis
All GALT news →About Galectin Therapeutics
Galectin Therapeutics develops carbohydrate-based medicines that target galectin proteins, mainly galectin-3. Its lead drug, belapectin, is being tested for advanced liver scarring linked to fatty liver disease and for certain cancers, including head and neck tumors. A partly owned subsidiary runs a discovery effort on oral compounds that block galectin-3. The company is based in the United States.
Based on the company's 10-K filed Mar 31, 2026.
Nasdaq · Healthcare
GALECTIN THERAPEUTICS INC (GALT)
What Is the Price Target for GALT?
SEPT Low Target
$11.00
SEPT Mid Target
$11.00
SEPT High Target
$11.00
Analyst Consensus
$11.00
Is GALT a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for GALT.
Start Free Trial →Is GALT Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$11.00
14
Moat Score
NONE
3/9
Piotroski Score
-32.8
Altman Z-Score
What Is Smart Money Doing with GALT?
Insider Signal
NEUTRAL
1 buys / 1 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Jamil Khurram | officer | Buy | 568 | $698.64 | May 26, 2026 |
| Jamil Khurram | officer | Sale | 568 | $2K | May 26, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →GALT Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
36.84%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for GALT
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for GALT, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 20:21:00 | $3.31 | 1,300 | $$4K | BUY |
| 17:30:55 | $3.36 | 4,936 | $$17K | SELL |
| 19:56:53 | $3.34 | 2,001 | $$7K | SELL |
| 19:31:40 | $3.38 | 1,189 | $$4K | BUY |
| 19:02:20 | $3.38 | 1,700 | $$6K | BUY |
5 dark pool trades shown · $$37K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for GALT
PREVIEWSEPT Investing provides real-time options flow tracking for GALT, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $5 | Dec 18 | 37 | $$10 | 1 | SWEEP |
| CALL | $5 | Dec 18 | 37 | $$30 | 3 | SWEEP |
| CALL | $5 | Dec 18 | 37 | $$10 | 1 | SWEEP |
3 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for GALECTIN THERAPEUTICS INC (GALT) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (0 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →GALT — frequently asked questions
What is GALT stock price today?
GALECTIN THERAPEUTICS INC (GALT) is at $3.29, down 2.66% (-$0.09) at the Nov 11, 2026 close.
Why is GALT stock moving today?
Latest GALT news — Nov 6, 2026: Galectin Therapeutics Shares Data at AASLD Liver Meeting 2026 · Nov 5, 2026: Galectin Therapeutics reports belapectin benefit in NAVIGATE trial analysis
What is the GALT price target?
The average analyst price target for GALT is $11.00, ranging from $11 to $11, based on 1 analysts.
What do analysts rate GALT?
Analyst ratings for GALT: 0 Buy, 1 Hold, 0 Sell — consensus Hold.
Did GALT beat earnings?
GALT last reported on Aug 14, 2026: EPS -$0.14 vs -$0.09 expected — a miss of 55.6%.
Does GALT pay a dividend?
Yes. GALT's dividend yield is 0.11%.
What are GALT support and resistance levels?
Support: $2.90, $2.50, $2.07. Resistance: $3.52, $4.00, $4.35.
What are insiders doing with GALT?
Insider activity: NEUTRAL, 1 buys and 1 sells in the last 90 days.
What is the latest news on GALT?
Nov 6, 2026: Galectin Therapeutics Shares Data at AASLD Liver Meeting 2026 · Nov 5, 2026: Galectin Therapeutics reports belapectin benefit in NAVIGATE trial analysis